RxDoctor Payments Data

Jessica Connett, MD

Dermatology · Wilmington, NCNPI 1053654053

Payments from drug & device makers

$2,300in general payments, 2019–2025

Across 113 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$771
  • Novartis$252
  • Galderma Laboratories, L.p.$213
  • Regeneron Healthcare Solutions, Inc.$159
  • Sun Pharmaceutical Industries Inc.$148
  • E.r. Squibb & Sons, L.L.C.$106
  • plus $651 from 14 others

What the payments were for

  • Food & beverage$2,14093%
  • Education$1607%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,300 in reported general payments places this provider in the 45th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$264,973
Medicare patients
737
Services billed
3,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib13$80,964
Fluorouracil73$4,297
Betamethasone Dipropionate49$2,169
Ketoconazole142$2,124
Metronidazole40$1,967
Fluocinonide58$1,963
Tretinoin34$1,611
Clobetasol Propionate23$1,439
Triamcinolone Acetonide107$1,059
Clindamycin Phosphate20$752
Mometasone Furoate37$606
Doxycycline Hyclate32$593
Mupirocin96$585
ValacyclovirValacyclovir Hcl34$530
Hydrocortisone67$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$771$80,96413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →